FAM111B and hepatocellular carcinoma: In summary, we determined that targeting FAM111B favours the inhibition of HCC progression by promoting RANBP9-induced MFN2 ubiquitinated degeneration and that sGLNP successfully delivered shFAM111B to inhibit HCC progression and enhance the effect of lenvatinib for HCC treatment.